Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2022 07:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b...
May 09, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
May 03, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

--Now Covered by the largest Pharmacy Benefit Manager in the United States and Humana Medicare----Expands Commercial coverage to 92% of total commercial lives----Doubles Medicare coverage from 7.1...
May 01, 2022 09:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up ---- All Patients with...
April 04, 2022 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...
March 29, 2022 07:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

-- Achieved $11.2 Million in Net Revenue in 2021 ---- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives ---- KPI-012 Phase 1b Clinical Data Accepted for...
March 23, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...
March 08, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a...
February 18, 2022 16:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement...
December 17, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...